Entries by hearten

Chief Scientific Officer

Company Background Enthera S.r.l (www.entherapharmaceuticals.com) is a biotech company that was founded around the novel technologies pioneered by Professor Paolo Fiorina (Harvard Medical School, University of Milan). The company recently completed a €35 million financing with participation by Sofinnova Partners, Abbvie Ventures, Roche Venture Fund and the JDRF T1D Fund. Enthera is developing a robust […]

Enthera Pharmaceuticals appoints Antonio Speziale as Chief Medical Officer

Antonio Speziale joins Enthera with drug development and commercialization experience from roles at Galapagos, Shire, Novartis, Genzyme and Wyeth Milan, Italy, 4 October 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, has appointed Antonio Speziale as Chief Medical Officer. […]

Clinical Trial Leader

Core purpose of the job Supporting quality and timely execution of pre-clinical and clinical studies through operational management. Principal accountabilites Management of all operational aspects related to the study conduct. Coordinate and supervise activities of multi-functional study team members. Working relationships Reporting to the Chief Medical Officer. Job requirements Degree in scientific disciplines (Medicine, Biology, […]

Enthera Pharmaceuticals opens early drug discovery unit at OpenZone life sciences campus to expand autoimmune disease research

The OpenZone drug discovery unit will be used to support Enthera’s new discovery program and accelerate its mission to identify new treatments for intractable autoimmune diseases Milan, Italy, 7 July 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today […]

Enthera Pharmaceuticals Appoints Claudia Nardini as Vice President of Research and Development

Milan, Italy, 1 April 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing novel disease-modifying biologics that re-establish stem cell capabilities to treat specific autoimmune diseases, today announces the appointment of Claudia Nardini as Vice President of Research and Development to support the Company’s manufacturing and regulatory divisions. Claudia has 25 years of experience in […]

Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million

The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]

Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development

Milan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.

Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease

Milan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.

UEG 2019

UEG Week Barcelona 2019 Barcelona, Spain 21-23 October 2019